Department of Translational Medicine, Translational Glycobiology Institute at FIU (TGIF), Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States; Department of Medical Biochemistry, Faculty of Medicine, South Valley University, Qena, Egypt.
Department of Life Sciences, Imperial College London, London, United Kingdom.
Adv Cancer Res. 2023;157:157-193. doi: 10.1016/bs.acr.2022.06.001. Epub 2022 Aug 8.
Melanoma is a highly aggressive skin cancer with poor outcomes associated with distant metastasis. Intrinsic properties of melanoma cells alongside the crosstalk between melanoma cells and surrounding microenvironment determine the tumor behavior. Galectin-3 (Gal-3), a ß-galactoside-binding lectin, has emerged as a major effector in cancer progression, including melanoma behavior. Data from melanoma models and patient studies reveal that Gal-3 expression is dysregulated, both intracellularly and extracellularly, throughout the stages of melanoma progression. This review summarizes the most recent data and hypotheses on Gal-3 and its tumor-modulating functions, highlighting its role in driving melanoma growth, invasion, and metastatic colonization. It also provides insight into potential Gal-3-targeted strategies for melanoma diagnosis and treatment.
黑色素瘤是一种侵袭性很强的皮肤癌，其远处转移与不良预后相关。黑色素瘤细胞的内在特性以及黑色素瘤细胞与周围微环境之间的相互作用决定了肿瘤的行为。半乳糖凝集素-3（Galectin-3，Gal-3）是一种β-半乳糖苷结合凝集素，已成为癌症进展的主要效应因子，包括黑色素瘤的行为。来自黑色素瘤模型和患者研究的数据表明，Gal-3 的表达在黑色素瘤进展的各个阶段都发生了失调，包括细胞内和细胞外。本综述总结了 Gal-3 及其肿瘤调节功能的最新数据和假说，强调了它在驱动黑色素瘤生长、侵袭和转移定植中的作用。它还提供了对黑色素瘤诊断和治疗中潜在 Gal-3 靶向策略的深入了解。
